Bayer halves the price of its contraceptive implant Jadelle® for women in developing countries

BayerBayer will halve the price of its contraceptive implant Jadelle until 2023 for women living in poor countries around the world. According to the Reproductive Health Supply Coalition the demand for implants is increasing continuously in these countries. Bayer's "Jadelle Access Program" aims to make this underutilized method more affordable and accessible to women there, ultimately helping them to expand their choice of contraceptive options.

"Our 'Jadelle Access Program' widens the contraceptive options available to women living in poor countries around the world, so they can choose a method that best suits their needs," said Dieter Weinand, member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division.

'Ensure healthy lifes and promote well-being for all at all ages', is one of the Sustainable Development Goals (SDGs) ratified in September 2015 by the United Nations. These goals set a large number of ambitious targets to be achieved by 2030. They all recognize "health" as a driver of global economic growth. Although only specifically covered by one goal, health is implicitly linked to most of the other 16 SDGs.

Bayer’s activities in family planning directly relate to the "Health" goal, as it covers among others child and maternal mortality and reproductive health. As a market leader in oral contraceptives, Bayer now has nearly 50 years of expertise in the field of family planning. For women in developing countries, Bayer supplies its different hormonal contraceptive methods to partners in international development cooperation at a preferential price. At the same time, Bayer is developing new concepts like the "Jadelle Access Program" to give women more family planning options.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

FDA approves once-daily Qtern (dapagliflozin and s…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of typ...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]